At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 329 enrolled
Drug / intervention
HNO Donor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systolic Function
In Brief
A Phase 2 clinical trial evaluating HNO Donor and Placebo for Heart Failure. Completed, enrolled 329 participants across 116 sites in 13 countries.
Detailed Summary
A Study to Evaluate Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of HNO Donor in Hospitalized Patients with Heart Failure and Impaired Systolic Function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesArgentina, Canada, Czechia, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartJan 2017
Primary CompletionJun 2019
Study CompletionNov 2019
TodayJul 2026
First PostedJan 10, 2017
Enrollment StartJan 13, 2017
Primary CompletionJun 23, 2019
Study CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.5 years ago
Interventions
HNO Donordrug
Infusion
Placebodrug
Infusion